International Journal of Radiation Oncology*Biology*Physics
Poster Viewing AbstractStereotactic Body Radiation Therapy (SBRT) Combined With Transarterial Chemoembolization (TACE) in BCLC Stage B and C Hepatocellular Carcinoma (HCC)
Section snippets
Purpose/Objective(s)
To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with transarterial chemoembolization (TACE) in BCLC stage B and C hepatocellular carcinoma.
Materials/Methods
During the period of 2008 to 2015, prospective data of 73 consecutive BCLC stage B and C HCC patients, who received single dose of TACE followed by SBRT 4-6 weeks later were analyzed. All patients had tumor size ≥ 5cm and at least 700 mL of non-HCC liver. Individuals with Child-Pugh (CP) score >B7, main portal vein thrombosis (PVT), infiltrative tumors or extensive extra-hepatic diseases were excluded. SBRT dose, range from 5-8 Gy x 6 fractions, or 4 Gy x 5-10 fractions, was individualized
Results
Median follow-up time was 17 months (range: 3-96 months). Patients’ characteristics were as follows: Median age was 60 years (range: 28-87); CP class A/B (n = 68/5); BCLC stage B/C (n = 52/21); TNM stage I-II/III/IV (n = 19/45/9); Solitary/Multifocal (n = 37/36); Portal vein thrombosis (n = 21). Median size of tumor was 11.5cm (range: 5-23.6cm) and median GTV size was 751cc (range: 55-4009cc). Median total equivalent dose in 2 Gy per fraction (EQD2, a/b = 3) given was 57.3 Gy (range: 28-105.6
Conclusion
Combined SBRT with TACE is safe and achieves favorable local control in BCLC stage B-C HCC. Further prospective studies on this approach are warranted.
References (0)
Cited by (0)
Author Disclosure: C. Chiang: None. A. Lee: None. K. Choi: None. S. Yeung: None. Y. Wong: None. W. Leung: None. W. Lee: None. M. Chan: None. S. Tung: None.